Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02735083 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Feb 2025 to Sep 2028v15
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 30 to confirmed 28 · Study sites: 18 to 16v14 Show 2 more changesShow less
    • Enrollment target: estimated 30 to confirmed 28
    • Study sites: 18 to 16
  3. Trial status: Active, Not Recruiting to Recruiting Primary and study completion dates: Mar 2040 to Feb 2025 · Start date: Nov 9, 2016 to Mar 10, 2021 · Study sites: 16 to 18v13 Show 3 more changesShow less
    • Primary and study completion dates: Mar 2040 to Feb 2025
    • Start date: Nov 9, 2016 to Mar 10, 2021
    • Study sites: 16 to 18
  4. Re-verified, no change to tracked fieldsv12
  5. Enrollment target: 300 to 30 Trial status: Enrolling by Invitation to Active, Not Recruiting · Secondary endpoints: details revised at 1 of 6 entries · Study title revisedv11 Show 3 more changesShow less
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Secondary endpoints: details revised at 1 of 6 entries
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

Show 9 earlier versionsHide 9 earlier versions
  1. Primary endpoint revised Study sites: 21 to 16 · Interventions: UCART19/ALLO-501 follow-up (Biological) to UCART19 follow-up (Biological) · Eligibility criteria expanded, about 9 words · 2 morev10 Show 5 more changesShow less
    • Study sites: 21 to 16
    • Interventions: UCART19/ALLO-501 follow-up (Biological) to UCART19 follow-up (Biological)
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: 7 to 6
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 22 to 21v9
  3. Study sites: 16 to 22v8
  4. Enrollment target: 200 to 300 Primary endpoint revised · Study sites: 11 to 16 · Interventions: UCART19 follow-up (Biological) to UCART19/ALLO-501 follow-up (Biological) · 4 morev7 Show 7 more changesShow less
    • Primary endpoint revised
    • Study sites: 11 to 16
    • Interventions: UCART19 follow-up (Biological) to UCART19/ALLO-501 follow-up (Biological)
    • Eligibility criteria revised
    • Secondary endpoints: 5 to 7
    • Study title revised
    • Collaborators expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Phase: Not applicable to Phase 1 Study sites: 10 to 11 · Interventions: UCART19 follow-up (Genetic) to UCART19 follow-up (Biological) · Secondary endpoints: details revised at 5 of 5 entriesv6 Show 3 more changesShow less
    • Study sites: 10 to 11
    • Interventions: UCART19 follow-up (Genetic) to UCART19 follow-up (Biological)
    • Secondary endpoints: details revised at 5 of 5 entries
  6. Study sites: 7 to 10v5
  7. Trial status: Recruiting to Enrolling by Invitation Site details revised at 7 of 7 sitesv4 Show 1 more changeShow less
    • Site details revised at 7 of 7 sites
  8. Study sites: 1 to 7 Start date: Nov 2016 to Nov 9, 2016 · Eligibility criteria shortened, about 11 words · Secondary endpoints revised (5)v3 Show 3 more changesShow less
    • Start date: Nov 2016 to Nov 9, 2016
    • Eligibility criteria shortened, about 11 words
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  9. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 2016 to Nov 2016 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date: Aug 2016 to Nov 2016
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the long-term safety and efficacy of UCART19 administration to patients with advanced lymphoid leukemia.
Trial Details
NCT Number NCT02735083
Lead Sponsor Institut de Recherches Internationales Servier
Collaborators: ADIR, a Servier Group company
Conditions Advanced Lymphoid Leukemia
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov